Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus

Annals of Pharmacotherapy

Volumn 31, Issue 6, 1997, Pages 671-676

  Sonnenberg, Gabriele E ^a   Garg, Dyal C ^b,c   Weidler, Donald J ^d,e   Dixon, Russell M ^f   Jaber, Linda A ^g   Bowen, Angela J ^h   DeCherney, G Stephen ⁱ   Mullican, William S ^j,k   Stonesifer, Larry D ^l  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Besselar Clinical Research Unit   (United States)

^c Clinical Research Services   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e MOREHOUSE SCHOOL OF MEDICINE   (United States)

^f Besselar Clinical Research   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

^h Middleton Foundation   (United States)

ⁱ MEDICAL CENTER OF DELAWARE   (United States)

^j GFI Pharmaceutical Services Inc   (United States)

^k MedisPhere Medical Research Center   (United States)

^l St Francis Hospital   (United States)

more..

Author keywords

Diabetes mellitus; Glimepiride

Indexed keywords

C PEPTIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; PLACEBO; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0030995605     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100601     Document Type: Article

References (20)

1. Goldberg RB, Holvey SM, Schneider J, The Glimepiride Protocol #201 Study Group. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996;19:849-56.
2. Rosenstock J, Samols E, Muchmore DB, Schneider J, The Glimepiride Study Group. Glimepiride, a new, once-daily sulfonylurea: double-blind, placebo-controlled study of NIDDM patients. Diabetes Care 1996;19: 1194-9.
3. 3H]glimepiride. Biochim Biophys Acta 1994;1191:278-90.
4. Sato J, Ohsawa I, Oshida Y, Sato Y, Sakamoto N. Comparison between effects of glimepiride and glibenclamide on in vivo insulin action. In: Sakamoto N, Alberti KGMM, Hotta N, eds. Pathogenesis and treatment of NIDDM and its related problems. 4th ed. New York: Excerpta Medica, 1994:341-8.
5. + channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in a dog. J Clin Invest 1992;89:2071-4.
6. Ballagi-Pordány G, Németh M, Aranyi Z, Kékesi E, Koltai MZ, Papp G, et al. Effects of glimepiride on the electrical activity of isolated rabbit heart muscle. Drug Res 1992;42:111-3.
7. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? JAMA 1989;261:3273-7.
8. Pullar T, Birtwell AJ, Wiles PG, Hay A, Feely MP. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther 1988;44:540-5.
9. Morgan CR, Lazarow A. Immunoassay of insulin: two antibody system. Diabetes 1963;12:115-26.
10. Prout J. Radioisotope measurements of insulin. In: Rothfeld B, ed. Nuclear medicine in vitro. Philadelphia: Lippincott, 1974:267.
11. Heding LG. Radioimmunological determination of human C-peptide in serum. Diabetologia 1975;11:541-8.
12. Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH. Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes 1977;26:22-9.
13. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin - pitfalls and limitations. Diabetes 1984;33:486-94.
14. Madsbad S, Hartling SG, Faber OK. C-peptide and proinsulin. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International textbook of diabetes mellitus. New York: John Wiley and Sons Ltd., 1992: 303-25.
15. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type 1 diabetic patients. J Clin Invest 1986;77:98-105.
16. Urquhart J. Role of patient compliance in clinical pharmacokinetics: a review of recent research. Clin Pharmacokinet 1994;27:202-15.
17. Sims EAH, Calles-Escandon J. Insulin, glucagon, and oral hypoglycemic agents in the treatment of diabetes mellitus. In: Munson PL, Mueller RA, Breese GR, eds. Principles of pharmacology: basic concepts and clinical applications. New York: Chapman and Hall, 1995:697-724.
18. Jaber LA, Antal EJ, Slaughter RL, Welshman IR. Comparison of pharmacokinetics and pharmacodynamics of short- and long-term glyburide therapy in NIDDM. Diabetes Care 1994;17:1300-6.
19. Glimepiride for NIDDM. Med Lett Drugs Ther 1996;38:47-8.
20. Draeger E. Clinical profile of glimepiride. Diabetes Res Clin Pract 1995; 28(suppl):S139-46.